Cara TherapeuticsNASDAQ: CARA

Shares of Cara Therapeutics Inc CARA tanked in early trading on Thursday, with the Dow shedding more than 100 points.

Cara Therapeutics said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its experimental drug did not demonstrate a meaningful clinical benefit compared to placebo.

Cara Therapeutics (CARA) reported a quarterly loss of $0.56 per share, which was higher than the Zacks Consensus Estimate of a loss of $0.38 per share. This is compared to a loss of $0.49 per share in the same quarter last year.

Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.

Cara Therapeutics, Inc. (NASDAQ:CARA ) Q4 2023 Earnings Call Transcript March 4, 2024 4:30 PM ET Company Participants Matt Murphy - Manager, IR Chris Posner - CEO Ryan Maynard - CFO Joana Goncalves - CMO Conference Call Participants Annabel Samimy - Stifel Joseph Stringer - Needham & Company Dennis Ding - Jefferies David Amsellem - Piper Sandler Operator Thank you for standing by, and welcome to Cara Therapeutics Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time all participants are in a listen-only mode.

Cara Therapeutics (CARA) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.56 per share a year ago.

STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update.

The headline numbers for Cara (CARA) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Cara Therapeutics (CARA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.08 per share a year ago.